BHVN:NYE-Biohaven Pharmaceutical Holding Co Ltd (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 15.75

Change

-0.27 (-1.69)%

Market Cap

USD 1.64B

Volume

1.86M

Analyst Target

USD 83.60
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson's disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities. It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin's lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors. The company has strategic partnerships with Merus N.V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
TECH Bio-Techne Corp

+0.13 (+0.26%)

USD 8.03B
RCUS Arcus Biosciences Inc

+0.15 (+1.75%)

USD 0.91B
NUVB Nuvation Bio Inc

+0.04 (+1.77%)

USD 0.77B
DNA Ginkgo Bioworks Holdings

+0.16 (+2.02%)

USD 0.46B
CYBN Cybin Inc

+0.78 (+11.61%)

USD 0.15B
ADCT ADC Therapeutics SA

+0.45 (+23.81%)

USD 0.14B
PLX Protalix Biotherapeutics Inc

+0.01 (+0.60%)

USD 0.13B
OSTX OS Therapies Incorporated

-0.05 (-3.05%)

USD 0.07B
ANRO Alto Neuroscience, Inc.

+0.01 (+0.40%)

USD 0.07B
ATNM Actinium Pharmaceuticals Inc

+0.12 (+7.19%)

USD 0.05B

ETFs Containing BHVN

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -57.83% 26% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.83% 26% F 1% F
Trailing 12 Months  
Capital Gain -59.94% 46% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.94% 46% F 2% F
Trailing 5 Years  
Capital Gain -69.68% 48% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -69.68% 48% F 4% F
Average Annual (5 Year Horizon)  
Capital Gain 32.36% 78% C+ 91% A-
Dividend Return 32.36% 78% C+ 90% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 96.11% 46% F 7% C-
Risk Adjusted Return 33.67% 89% A- 51% F
Market Capitalization 1.64B 96% N/A 65% D

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.